{
    "nctId": "NCT05697198",
    "briefTitle": "PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine",
    "officialTitle": "PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine",
    "overallStatus": "RECRUITING",
    "conditions": "Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2500,
    "primaryOutcomeMeasure": "The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period",
    "eligibilityCriteria": "Case Inclusion Criteria\n\n* Any gender, race, or ethnicity is acceptable\n* Must be at least 18 years of age\n* All subjects must fall into the following group:\n\nAll Cases will be classified as following cohorts\n\nCohort lung cancer - Subject must meet the following criteria:\n\n* Recently diagnosed advanced lung cancer\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable) and/or on treatment\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nGyn malignancies (list ovarian and uterine cancer separately)\n\n* Recently diagnosed advanced gynecological malignancies\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nGastrointestinal malignancies Cohort (list all cancers separately-colorectal, gastric, esophageal and pancreatic)\n\n* Recently diagnosed advanced gastrointestinal malignancy\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nMelanoma Cohort\n\n* Recently diagnosed advanced melanoma\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nBreast cancer Cohort\n\n* Recently diagnosed advanced breast cancer\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nHead and neck cancer Cohort\n\n* Recently diagnosed advanced head and neck cancer\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nSarcoma and soft tissue cancer cohort\n\n* Recently diagnosed advanced cancer\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nProstate cancer\n\n* Recently diagnosed advanced cancer\n* Locally advanced and metastatic solid tumors\n* Treatment na\u00efve (not yet treated or tumor removed; biopsy acceptable).\n* Previously Treated: If treated, must have developed resistance and testing will be looking at change in therapy based on results of testing\n\nAdditional Requirements\n\n* Subjects must be diagnosed by appropriate histopathology\n* Subjects can have any concurrent diseases\n* Must voluntarily sign and understand the most current Institutional Review Board/Independent Ethics Committee (IRB/IEC) - approved Informed Consent Form (ICF) prior to study participation. Witness must sign the informed consent form if the subject is illiterate.\n\nExclusion Criteria\n\n* Subjects incapable of understanding the items listed in the ICF and the consent process\n* Pregnant females\n* Subjects with a history of or known psychiatric illness that deems them unable to consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}